Merck's WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) | Business
RAHWAY, N.J.--(BUSINESS WIRE)--Oct 21, 2023--
Source: valdostadailytimes.com